The YouTuber identifies Adaptive Biotech Technologies (ADPT) as a potential 10x stock by 2030, based on a pattern where the stock price has been flat for years while the underlying business (revenue growth) has been growing significantly. He highlights their FDA-cleared ClonoSEQ test for blood cancer, which has low market penetration and is expected to become profitable this year, acting as a catalyst for market re-evaluation. Despite acknowledging high risk and competition, he believes the company's unique product and market position make it an attractive investment.
“And it's a stock that could literally save your life. Like ADPT, a company called Adaptive Biotech Technologies.” — ▶ 10:00